EC HEALTHCARE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.34 HKD | +3.88% |
|
+12.61% | -22.99% |
| Jan. 31 | EC Healthcare Announces Change of Principal Place of Business in Hong Kong, with Effect from 1 February 2024 | CI |
| Jan. 24 | EC Healthcare's Overall Sales Volume Rises 7% in Q4 2023 | MT |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,539 | 3,350 | 7,261 | 9,828 | 7,431 | 1,588 | - | - |
| Enterprise Value (EV) 1 | 5,539 | 3,091 | 6,853 | 9,191 | 7,431 | 1,588 | 1,588 | 1,588 |
| P/E ratio | 16 x | 11.7 x | 36.3 x | 49.6 x | 106 x | 32.1 x | 7.84 x | 5.28 x |
| Yield | 5.99% | 6.76% | 2.35% | 1.73% | 1.59% | 2.95% | 6.47% | 9.23% |
| Capitalization / Revenue | 3.02 x | 1.72 x | 3.49 x | 3.37 x | 1.92 x | 0.37 x | 0.31 x | 0.28 x |
| EV / Revenue | 3.02 x | 1.59 x | 3.29 x | 3.15 x | 1.92 x | 0.37 x | 0.31 x | 0.28 x |
| EV / EBITDA | 11 x | 5.04 x | 11.5 x | 11.4 x | 7.99 x | 1.33 x | 1.12 x | 1.02 x |
| EV / FCF | -71.1 x | 6.1 x | 14.1 x | 26.4 x | 38.3 x | 4.69 x | 3.77 x | 2.3 x |
| FCF Yield | -1.41% | 16.4% | 7.08% | 3.79% | 2.61% | 21.3% | 26.5% | 43.5% |
| Price to Book | 5.51 x | 3.34 x | 5.72 x | 5.22 x | 4.01 x | 0.89 x | 0.87 x | 0.83 x |
| Nbr of stocks (in thousands) | 948,524 | 985,277 | 1,071,016 | 1,178,372 | 1,185,211 | 1,185,211 | - | - |
| Reference price 2 | 5.840 | 3.400 | 6.780 | 8.340 | 6.270 | 1.340 | 1.340 | 1.340 |
| Announcement Date | 6/26/19 | 6/29/20 | 6/29/21 | 6/23/22 | 6/23/23 | - | - | - |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,837 | 1,949 | 2,080 | 2,920 | 3,875 | 4,279 | 5,043 | 5,751 |
| EBITDA 1 | 501.5 | 613 | 594.4 | 804.5 | 929.8 | 1,190 | 1,416 | 1,555 |
| EBIT 1 | 452.5 | 543.1 | 284.6 | 371 | 187.5 | 256.5 | 423.4 | 589 |
| Operating Margin | 24.64% | 27.87% | 13.68% | 12.71% | 4.84% | 5.99% | 8.4% | 10.24% |
| Earnings before Tax (EBT) 1 | 450.1 | 360.5 | 265.9 | 321.4 | 136.2 | 91.65 | 327.1 | 469.1 |
| Net income 1 | 361.1 | 286.6 | 192.9 | 197.5 | 69.65 | 47.32 | 201.2 | 300.6 |
| Net margin | 19.66% | 14.71% | 9.27% | 6.76% | 1.8% | 1.11% | 3.99% | 5.23% |
| EPS 2 | 0.3660 | 0.2900 | 0.1870 | 0.1680 | 0.0590 | 0.0418 | 0.1710 | 0.2538 |
| Free Cash Flow 1 | -77.94 | 506.7 | 484.9 | 348.1 | 194.3 | 338.4 | 421 | 690.4 |
| FCF margin | -4.24% | 26% | 23.31% | 11.92% | 5.01% | 7.91% | 8.35% | 12% |
| FCF Conversion (EBITDA) | - | 82.65% | 81.58% | 43.27% | 20.89% | 28.43% | 29.72% | 44.41% |
| FCF Conversion (Net income) | - | 176.81% | 251.44% | 176.25% | 278.9% | 715.2% | 209.23% | 229.64% |
| Dividend per Share 2 | 0.3500 | 0.2300 | 0.1590 | 0.1440 | 0.1000 | 0.0395 | 0.0868 | 0.1237 |
| Announcement Date | 6/26/19 | 6/29/20 | 6/29/21 | 6/23/22 | 6/23/23 | - | - | - |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: März | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S2 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|
| Net sales | 1,118 | 830 | 797.4 | 1,283 | 1,444 | 1,476 | 1,982 | - |
| EBITDA | - | 241.1 | - | 399.3 | 323.2 | - | - | - |
| EBIT | - | 205.6 | - | 215.1 | 248.6 | - | - | - |
| Operating Margin | - | 24.77% | - | 16.76% | 17.22% | - | - | - |
| Earnings before Tax (EBT) | - | 111.6 | - | 205 | 231.7 | 89.69 | - | - |
| Net income | - | 89.07 | - | 148.9 | 160.2 | 37.29 | -10.39 | - |
| Net margin | - | 10.73% | - | 11.61% | 11.1% | 2.53% | -0.52% | - |
| EPS 1 | 0.2000 | 0.0900 | - | - | 0.1400 | 0.0280 | - | 0.0300 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/26/19 | 6/29/20 | 11/26/20 | 6/29/21 | 11/29/21 | 6/23/22 | 6/23/23 | - |
1HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 0.1 | 0.1 | - |
| Net Cash position 1 | - | 258 | 409 | 637 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | 0.000084 x | 0.000071 x | - |
| Free Cash Flow 1 | -77.9 | 507 | 485 | 348 | 194 | 338 | 421 | 690 |
| ROE (net income / shareholders' equity) | 38.8% | 28% | 17% | 12.5% | 3.73% | 2.73% | 8.5% | 11.8% |
| ROA (Net income/ Total Assets) | 16.7% | 11.7% | 6.08% | 4.57% | 1.34% | 4.93% | 7.55% | 10.9% |
| Assets 1 | 2,165 | 2,451 | 3,173 | 4,326 | 5,187 | 959.1 | 2,665 | 2,769 |
| Book Value Per Share 2 | 1.060 | 1.020 | 1.180 | 1.600 | 1.560 | 1.500 | 1.550 | 1.610 |
| Cash Flow per Share 2 | - | 0.5800 | 0.6000 | 0.5200 | - | 0.5700 | 0.7600 | - |
| Capex 1 | 316 | 69.8 | 136 | 260 | 411 | 692 | 735 | 750 |
| Capex / Sales | 17.23% | 3.58% | 6.53% | 8.91% | 10.61% | 16.16% | 14.57% | 13.04% |
| Announcement Date | 6/26/19 | 6/29/20 | 6/29/21 | 6/23/22 | 6/23/23 | - | - | - |
1HKD in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1.34
HKD
Average target price
2.095
HKD
Spread / Average Target
+56.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.99% | 203M | |
| -14.20% | 567M | |
| +41.52% | 472M | |
| +9.91% | 294M | |
| -25.53% | 93.09M | |
| -4.20% | 80.02M | |
| -10.34% | 66.43M | |
| -19.67% | 66.28M | |
| 0.00% | 61.81M | |
| -29.63% | 59.55M |
- Stock Market
- Equities
- 2138 Stock
- Financials EC Healthcare
